McKesson Corporation reported its fiscal 2026 third-quarter results today and raised its full‐year adjusted EPS guidance. The company hosted a live webcast at 4:30 PM ET to discuss performance, which included double-digit revenue growth driven by both its pharmaceutical distribution and technology services segments. Executive commentary highlighted strong demand from retail and institutional pharmacy customers, and management raised the full-year adjusted EPS outlook by 10 cents, reflecting confidence in margin expansion through operating efficiencies and continued volume gains.

Analysts expect McKesson to deliver a 15.9% increase in EPS to $9.31 and a 10.8% rise in revenue to $105.54 billion for Q3, underscoring consensus confidence in the company’s ability to leverage scale in its core distribution business. Estimates for EPS have remained unchanged over the past 30 days, suggesting stability in forecasted profitability. Market observers note that unchanged consensus figures often precede modest upside surprises, as management tends to outperform conservative analyst projections in periods of strong underlying demand.

McKesson’s current P/E ratio stands at 26.03, reflecting investor willingness to pay a premium for its earnings growth profile. The company’s negative debt-to-equity ratio of –5.63 highlights a capital structure in which lease liabilities offset traditional debt, while a current ratio of 0.88 signals liquidity slightly below the ideal threshold. Together with a price-to-sales ratio of 0.27 and an enterprise-value-to-sales multiple of 0.29, these metrics suggest that McKesson remains attractively valued relative to peers, though investors will monitor cash flow generation and working capital trends closely as Q3 results are fully disclosed.